Home›Diabetes & Endocrinology› Mongolian Medicine Compounds Show Immunomodulatory Potential in Sepsis, But Direct Evidence Remains Scarce
Mongolian Medicine Compounds Show Immunomodulatory Potential in Sepsis, But Direct Evidence Remains ScarceTraditional Mongolian Medicine shows potential for treating sepsis models
Frontiers in MedicinePublished October 3, 2026Study authors: Shaohua Cui, Di Wu, Yongli Zhang, Lixia GengDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret Mongolian Medicine sepsis data as hypothesis-generating only; direct evidence is scarce.
This narrative review synthesizes evidence on Traditional Mongolian Medicine compounds for immunomodulatory potential in sepsis. The reviewed agents include Daruqi particles, HHQG, Hohgardi-9, Nagab-9, Monflu, Batri-7, Qiqirigan-8, and selected extracts such as quercetin, berberine, and geniposide. The authors examined secondary outcomes related to NF-kB/MAPK signaling, myeloid-cell infiltration, neutrophil extracellular traps, redox regulation, and lipid metabolism.
The central finding is that direct sepsis-specific evidence is scarce. Most included studies were conducted in lipopolysaccharide-induced acute lung injury, organ-injury, enteritis, inflammatory, or metabolic models rather than in sepsis itself. No pooled effect sizes, p-values, or confidence intervals were reported.
The authors explicitly note multiple limitations: lack of direct sepsis-specific evidence, lack of assessment of polymicrobial infection, pathogen clearance, survival, late immunosuppression, and human immune endotypes. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. Funding and conflicts of interest were also not reported.
The authors state that the literature supports an ethnopharmacology-informed research agenda, not therapeutic efficacy in sepsis. Clinicians should interpret these findings as hypothesis-generating only. The absence of human sepsis data, survival outcomes, and safety reporting precludes any clinical recommendation for these agents in sepsis management.
How this fits prior evidence
This narrative review extends prior coverage of sepsis diagnostics and biomarkers by shifting focus to Traditional Mongolian Medicine compounds as potential immunomodulators. It aligns with the previously noted gap between discovery and clinical deployment in sepsis biomarkers, as direct sepsis-specific evidence for these compounds remains scarce. The review also echoes prior coverage of quercetin in premature ovarian insufficiency models, where evidence certainty was low, by similarly reporting only preclinical model data without human sepsis outcomes. Unlike prior coverage of POCUS for source identification or PNI for mortality risk, this review does not provide clinical decision-support data.
Sepsis is a life-threatening reaction to infection that can cause rapid organ failure. While doctors are looking for ways to manage the intense inflammation it causes, researchers are currently looking at traditional Mongolian medicines to see if they can help. These treatments include substances like quercetin, berberine, and geniposide.
Researchers found that these compounds show potential to regulate the immune system in laboratory models. Specifically, they may help with things like lipid metabolism and the way cells respond to injury. However, it is important to note that these findings come from lab models, not from human patients. Most of the evidence comes from studies on lung injury or metabolic issues rather than direct sepsis cases.
Because of these limitations, the current research does not yet prove that these treatments work as a cure for human sepsis. The study did not look at how well these treatments clear infections or if they could cause long-term issues in the immune system. For now, these findings serve as a starting point for future research into natural compounds.
What this means for you:
Traditional Mongolian medicines show promise in lab models for sepsis, but more human research is needed.
Common questions
Can these traditional medicines treat sepsis in humans?
Current evidence is not enough to say if these treatments work for humans. Most of the research was done in lab models rather than in people. The study did not look at how well these medicines clear infections or if they would be safe for human patients with sepsis.
What specific ingredients were studied for sepsis?
The research looked at several components of Traditional Mongolian Medicine. These include quercetin, berberine, and geniposide, along with other specific extracts like Daruqi particles and Hohgardi-9. These were studied for their potential to manage immune responses.
What are the limitations of this research?
The study had several limitations. It lacked direct evidence from human sepsis cases, did not look at how the body clears pathogens, and did not assess long-term effects on the immune system. It also did not test how these treatments work against multiple types of infections at once.
Sepsis is a heterogeneous, time-dependent syndrome in which inflammatory injury, immune suppression, endothelial dysfunction, metabolic disturbance, and barrier failure may coexist. This narrative review evaluates whether current pharmacological evidence provides a defensible basis for investigating Traditional Mongolian Medicine as an adjunctive source of immunomodulatory candidates in sepsis. A concise account of sepsis immunopathology is used as an interpretive framework, after which evidence from named Mongolian formulas, extracts, medicinal materials, and isolated constituents is mapped according to ethnomedical specificity, model directness, and study-design limitations. Direct sepsis-specific evidence is scarce. Daruqi particles, HHQG, Hohgardi-9, Nagab-9, Monflu, Batri-7, Qiqirigan-8, and selected extracts have mainly been studied in lipopolysaccharide-induced acute lung injury, organ-injury, enteritis, inflammatory, or metabolic models. These studies suggest effects on NF-κB/MAPK signaling, myeloid-cell infiltration, neutrophil extracellular traps, redox regulation, and lipid metabolism, but generally do not assess polymicrobial infection, pathogen clearance, survival, late immunosuppression, or human immune endotypes. Widely distributed compounds such as quercetin, berberine, geniposide, and gallate are therefore treated only as non-specific constituent-level evidence of pharmacological plausibility. We propose candidate-specific priorities for chemical standardization, rigorous sepsis modeling, pharmacokinetic and safety evaluation, and biomarker-guided translation. The current literature supports an ethnopharmacology-informed research agenda, not therapeutic efficacy in sepsis.
